Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $56.9 million versus the consensus estimate of $67.8 million.

GUIDANCE:

Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of $209.1 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.